In melanoma mouse models, 9-ING-41 downregulates the expression of inhibitory immune checkpoints including PD-1 and LAG-3, resulting in synergistic anti-tumor activity when administered in combination with immune checkpoint inhibitors [79]. This evidence concerns the gene LAG3 and melanoma.